How many email patterns does SciNeuro Pharmaceuticals use?

SciNeuro Pharmaceuticals uses 1 known email pattern.

What domain does SciNeuro Pharmaceuticals use for work emails?

SciNeuro Pharmaceuticals uses scineuro.com for work email addresses.

Most Common Email Formats at SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals's most common email format is First.Last@scineuro.com (ex. John.Doe@scineuro.com), used for 100% of scineuro.com addresses. SciNeuro Pharmaceuticals uses 1 email pattern.

@scineuro.com

1 pattern

Format	Example	Share of scineuro.com
First.Last@scineuro.comMost common	John.Doe@scineuro.com	100%

Need a specific person's email?

Browse SciNeuro Pharmaceuticals's employee directory (about 32 employees) and reveal verified emails free.

Frequently Asked Questions

What does SciNeuro Pharmaceuticals do?

SciNeuro Pharmaceuticals was founded in 2020 and operates in the Biotechnology Research industry, alongside similar companies like Roche, UCB and Takeda. You can visit scineuro.com. Explore SciNeuro Pharmaceuticals's company overview page for more information.

What is SciNeuro Pharmaceuticals's email address format?

SciNeuro Pharmaceuticals's email format typically follows the pattern of First.Last@scineuro.com; this email format is used 100% of the time. Looking for more contact data? Unlock accurate emails and phone numbers from millions of profiles verified in real-time.

How many employees does SciNeuro Pharmaceuticals have currently?

SciNeuro Pharmaceuticals has approximately 32 employees as of November 2026. Key team members to contact include Chief Financial Officer: H. W., Vp Clinical Pharmacology/Dmpk: H. L. and Head Of Portfolio And Partnership: J. Y. For more team information and contact data, explore SciNeuro Pharmaceuticals's employee directory with LeadIQ.

SciNeuro Pharmaceuticals Email Format

Biotechnology ResearchMaryland, United States11-50 Employees

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on therapies for neurodegenerative diseases. Based in Rockville, Maryland and founded in 2020, the company has developed a pipeline that moves from discovery to clinical development, targeting three disease-driving mechanisms: neurovascular inflammation, proteinopathy, and immune response. Its objective is to deliver disease-modifying treatment options for Alzheimer's disease, Parkinson's disease, and other central nervous system disorders.

Recently, SciNeuro identified a new de novo amyloid beta antibody program and announced an exclusive worldwide licensing and collaboration with Novartis Pharma AG to advance this program for Alzheimer's disease. That collaboration with a major pharmaceutical partner indicates external support for advancing its CNS-focused research.

Most common format

First.Last@scineuro.com

Example: John.Doe@scineuro.com

1 pattern. See all formats

Verify a SciNeuro Pharmaceuticals email address

Free with a LeadIQ account. No credit card.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

B2B data verified in real-time
Sync data to your CRM, & add it to an outreach sequence in one click
Integrations with your tech stack for optimal efficiency
A patented AI cold email generator
Account & contact-level job change tracking

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Most Common Email Formats at SciNeuro Pharmaceuticals

@scineuro.com

Need a specific person's email?

Frequently Asked Questions

What does SciNeuro Pharmaceuticals do?

What is SciNeuro Pharmaceuticals's email address format?

How many employees does SciNeuro Pharmaceuticals have currently?

SciNeuro Pharmaceuticals Email Format

Ready to create more pipeline?

Everything for prospecting,in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Everything for prospecting,
in one platform.